When to Switch a Drug Class in Psoriasis Treatment
Experts conclude the series discussing how to approach switching psoriasis treatments.
Read More
Warnings and Precautions for Newer Psoriasis Treatments
Experts discuss package warnings associated with bimekizumab and how they inform patients of them.
Exploring Innovation: Recent Approvals and Novel Approaches to Psoriasis Treatment
Experts discuss bimekizumab for the treatment of psoriasis highlighting is efficacy over other treatments.
Understanding Biologics for Patients With IBD
Experts discuss the warnings regarding IL-17 blockers and inflammatory bowel disease.
Infectious Diseases and Biologic Treatment Selection
Experts emphasize the importance of collaboration with infectious disease specialists for patients with tuberculosis, while highlighting the low reactivation rates in newer agents.
Unraveling Boxed Warnings: Exploring/Examining Risks in Biologic Treatment Classes
Experts highlight how a history of cancer may impact psoriasis treatment decisions while touching on the safety profiles of newer IL agents.
Understanding Comorbidities: Impact on Biologic Treatment Selection
Experts discuss common comorbidities for patients with plaque psoriasis and how they can impact treatment decisions.
Benefits of IL Therapies in Patients with PP
Experts discuss the landscape of IL therapies for the treatment of psoriasis, highlighting their improved safety and efficacy over prior agents.
Biologics for Psoriasis: TNF Blockers
Experts discuss the use of TNF blockers in treating plaque psoriasis and their limited but important uses today.
Screening for PsA and Selecting Right Biologic Therapy
Dermatologist and rheumatologist Saakshi Khattri highlights the importance of screening psoriasis patients for psoriatic arthritis and how that may impact treatment decisions.
Choosing the Right Psoriasis Treatment: Tailoring Therapy to Patient Characteristics
Experts discuss the plethora of treatment options for psoriasis, including topicals, oral therapies, phototherapy, and biologics.